Poster Topical Area: Methods and Protocols

Location: Hall D

Poster Board Number: 682

P15-021 - A novel efficacy test for bioactive soybean genistein leads to a personalized therapeutic approach in triple-negative breast cancer patients.

Monday, Jun 11
8:00 AM – 3:00 PM

Objectives: Triple-negative breast cancer (TNBC) is a highly malignant cancer with poor prognosis in part due to the lack of hormone target-directed treatment opportunities such as with the estrogen antagonist, tamoxifen (TAM). Our publishedresults have shown that bioactive dietary components such as soybean genistein (GE) can resensitize TAM-induced anti-hormone therapy through regulation of epigenetic mechanisms in ER-negative breast cancer both in vitro and in vivo. Although dietary GE intervention has shown promising cancer preventive/therapeutic effects, research studies designed to test therapeutic efficacy of bioactive GE in TNBC patients are largely neglected. We have assembled a cross-functional team to develop a novel research plan that integrates multiple convenient tests to measure the efficacy of bioactive soybean GE leading to an optimized personalized treatment plan in TNBC patients.

In this study, we aim to identify the optimal GE responders and irresponsive individuals from randomly selected healthy female subjects by testing the S-equol-producing status in the urine, the specific microbiota in the stool and epigenetic modulator changes in the blood. We hypothesize that these novel measures will help to identify potential population that can efficiently utilize GE and maximize its chemopreventive and therapeutic effects against breast cancer.

The specific experimental designs of this study are delineated in Fig. 1.

1. Identify the optimal GE responders and irresponsive individuals by evaluating the effects of a four-week soy diet intervention on the microbiota in the stool, the S-equol-producing status in the urine and epigenetic modulator changes in the blood in 10 healthy female adults.

2.Assess the efficacy of dietary GE-mediated therapeutic regimen on TNBC xenografts in humanized germ-free mice.

Significance: This study will facilitate to develop a novel personalized therapeutic approach by using bioactive dietary GE and conventional anti-hormone treatment in refractory TNBC guided by a fast, convenient and cost-effective individualized screening and measurement.

This abstract is for the ILSI NA Research Challenge.

Funding Source: NIH R01 CA178441; R01 CA204346 and K01 AT009373
Research design

CoAuthors: Trygve Tollefsbol – UAB

Yuanyuan Li

Birmingham, Alabama